Trials / Recruiting
RecruitingNCT05940441
A Prospective Exploratory Clinical Study of Metronomic Capecitabine as Adjuvant Therapy in Locoregionally Advanced Hypopharyngeal Carcinoma
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 74 (estimated)
- Sponsor
- Eye & ENT Hospital of Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To explore whether the adjuvant therapy of metronomic capecitabine could improve the disease-free survival of locoregionally advanced hypopharyngeal carcinoma (stage IV：T4N0-1M0，anyTN2-3M0).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Capecitabine 500Mg Oral Tablet | 650 mg/m² body surface area twice daily for 1 year |
Timeline
- Start date
- 2023-07-01
- Primary completion
- 2025-07-01
- Completion
- 2027-07-01
- First posted
- 2023-07-11
- Last updated
- 2023-07-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05940441. Inclusion in this directory is not an endorsement.